FOSUN HEALTH Logo

Atrial Fibrillation & Arrhythmia Treatment

catalogue

Atrial Fibrillation & Arrhythmia Treatment

Atrial Fibrillation & Arrhythmia Treatment

Treatment for atrial fibrillation answers two questions that are asked in different rooms. One is about the rhythm itself: is it better to slow it down and leave it irregular, or to try to restore and keep a normal rhythm — and if so, with drugs, with a shock, or with a catheter. The other is about the clot: what will be done to reduce the risk of a stroke, and for how long. The two answers are independent, and patients are often surprised to find that a successful procedure does not by itself end the second conversation. This page compares the options, and states plainly what each of them does not do.

Two strategies, and a third decision that runs alongside them

Two strategies sit at the centre of rhythm treatment, and they differ in intent rather than in intensity. Rate control accepts that the atria will keep fibrillating and works instead on the pulse reaching the wrist, slowing the ventricular response so that the heart is not working at a permanent disadvantage. Rhythm control goes after the rhythm itself — either by converting it and keeping it converted with medication, or by removing the tissue that starts it. Neither is an escalation of the other; both are legitimate destinations.

Which one is chosen depends less on the electrocardiogram than on the patient. Age, how long the rhythm has been present, the size of the atrium, other heart disease, how badly the symptoms interfere and what the patient is prepared to take on all enter the decision — and so does the patient's own reading of the symptom burden described on the symptoms page. An older patient with few symptoms and an enlarged atrium may do very well with rate control alone. A younger patient whose episodes stop work may reasonably decide to go after the rhythm, knowing that the procedure carries its own risks and may need repeating.

Strategy What it aims at, and how What it does not do
Rate control A slower, more comfortable pulse without trying to change the rhythm — usually a beta-blocker or a heart-selective calcium-channel blocker first, with digoxin or a combination added when needed It does not restore a normal rhythm, and by itself it does not reduce stroke risk — anticoagulation is decided separately
Rhythm control A normal rhythm restored and, where possible, maintained — with antiarrhythmic medication, electrical cardioversion, or catheter ablation with pulmonary vein isolation It does not guarantee that the rhythm stays normal; how long it holds depends on the atrial substrate and on the triggers as much as on the treatment

The decision about the clot runs in parallel, and it is worth stating at the outset because patients routinely assume it is bundled with the first. Anticoagulation is chosen from the stroke-risk assessment, not from whether the rhythm was successfully treated. Restoring a normal rhythm does not automatically retire the anticoagulant, and a patient whose rhythm has been stable for years may still be taking one. That part of the plan is set out in full in the section on stroke prevention below.

Rate control: what adequate actually means

Rate control is the older strategy and, for many patients, the sensible one. Its aim is not a perfect number but a pulse slow enough that the heart fills properly between beats, the patient is not breathless and the muscle is not being driven continuously. What counts as adequate is judged from symptoms, from the rate recorded across an ordinary day, and from how the heart responds to exertion — not from a single reading taken while sitting still.

The medicines work at the gateway between atria and ventricles. Beta-blockers are usually first, because they also steady the rate during exertion; a heart-selective calcium-channel blocker is the alternative when beta-blockers are not tolerated or are unsuitable. Digoxin is added in some patients, particularly those who are less active or who have heart failure, because it slows conduction without the same effect on blood pressure. Combinations are common, and adjusting them is a normal part of follow-up rather than a sign that something has gone wrong.

Two limits are worth knowing. Rate control does not restore a normal rhythm, so the atria keep fibrillating and the process that forms clots continues — which is why it never substitutes for the anticoagulation decision. And in a minority of patients the rate cannot be controlled adequately with medication at all, or the drugs cannot be tolerated. In that situation a deliberate, irreversible step can be taken: ablating the AV node so the ventricles receive no atrial impulses, and implanting a pacemaker to set a steady rate. It is a last resort with a permanent consequence — the patient becomes pacemaker-dependent, and a difficult rhythm problem is exchanged for a paced rhythm that is dependable.

Rhythm control: three tools, and an honest caveat

Rhythm control means trying to restore a normal rhythm and then keep it. It has three tools, used in sequence or in combination depending on the patient.

Tool What it involves Where it fits
Antiarrhythmic medication A drug taken regularly to prevent episodes — flecainide or propafenone where the heart muscle is normal, amiodarone or sotalol where it is more compromised Usually the first step towards rhythm control, and often continued after a cardioversion or an ablation
Electrical cardioversion A controlled shock delivered under sedation to reset the rhythm; when it works, it works at once For a rhythm that has become persistent, or for a patient who is unstable; it does not by itself prevent the rhythm from returning
Catheter ablation A procedure that isolates the pulmonary vein openings from the rest of the atrium, described in the next section For symptomatic patients whose rhythm persists or returns despite medication, and increasingly as a first choice in selected patients

The honest caveat belongs with the table. Restoring a normal rhythm is easier than keeping one, and a normal rhythm is not automatically better than a well-controlled irregular one. Comparisons between the two strategies across broad groups of patients found that rhythm control did not prolong life for everyone, which is why the choice is guided by symptoms, age, how long the rhythm has been present and what the patient wants. For a patient whose symptoms are already well controlled on rate-controlling drugs, adding a rhythm-control strategy is a choice rather than a necessity.

Two practical points follow. Cardioversion carries a small but real risk of dislodging a clot that has formed in the appendage, so the imaging and anticoagulation arrangements made before and after a shock, described on the diagnosis page, are the safety of the procedure rather than optional formalities. And a patient who is cardioverted with no plan for what comes next will often be back in the same rhythm within months; the longer-term decision is made at the same time, not afterwards.

Catheter ablation and pulmonary vein isolation

Catheter ablation is the most direct answer to the rhythm. The insight behind it is that in most patients the episodes are started by rapid electrical activity in the muscle sleeves where the pulmonary veins join the left atrium. Ablating — creating small scars around — those openings disconnects the triggers from the rest of the atrium. The procedure is called pulmonary vein isolation, and it is the foundation of every ablation strategy for atrial fibrillation.

The approach is the same as for an electrophysiology study: catheters are passed through the veins at the groin into the heart. The energy used to make the scars is either radiofrequency, which heats the tissue, or cryoenergy, which freezes it. A balloon-shaped device can deliver the cryo lesions around each vein in a small number of applications, while radiofrequency is applied point by point around each opening. Which is used depends on the anatomy and on the experience of the centre; neither has a general advantage over the other, and both are aimed at the same result.

The patients who gain most are reasonably well defined: those whose symptoms continue despite medication, whose heart is not severely enlarged, and whose pattern is still paroxysmal. Ablation is also performed for persistent atrial fibrillation, though the procedure is usually longer, may involve additional lines inside the atrium in addition to isolating the veins, and is more likely to need repeating. Where an atrial flutter circuit is present it can be interrupted directly, and because flutter and fibrillation so often coexist, both are frequently treated in a single sitting.

Two things belong in any conversation before the decision. The first is that ablation is a procedure with real risks — bleeding or bruising at the puncture sites, fluid collecting around the heart, damage to structures lying near the veins, and, rarely, injury to the oesophagus or to the nerve that controls the diaphragm — and weighing those against the expected benefit is a discussion, not a formality. The second is that the result is measured in terms of freedom from the rhythm, with or without continuing medication, and it is not permanent for everyone: the ablated tissue can reconnect, and a repeat procedure is a normal part of the pathway rather than evidence that the first one failed.

Stroke prevention: the decision almost everyone faces

The stroke-prevention decision is the one part of atrial fibrillation care that is considered for almost every patient, including those who feel nothing at all. It is based on the risk profile rather than on symptoms, and it is revisited whenever that profile changes.

The mainstay is anticoagulation — medication that limits clot formation rather than dissolving clots that already exist. Two families are used. Warfarin requires regular blood tests and interacts with food and with other medicines, but remains the appropriate choice for some patients, particularly those with a mechanical valve or with certain forms of valve disease. The direct oral anticoagulants are taken at fixed doses without routine monitoring. Which one is suitable is decided with kidney function, the other medicines the patient takes, and the patient's ability to attend monitoring appointments all taken into account.

One misconception is worth correcting directly. Aspirin is not a substitute. It does not provide adequate protection against the kind of clot that forms in the atrium, and taking it in place of an anticoagulant leaves the main risk insufficiently covered. A second misconception is that a successful ablation removes the need. For many patients the risk factors that made anticoagulation appropriate are still there afterwards, and so is the anticoagulant — at least until the question is formally reviewed.

For a minority of patients long-term anticoagulation is genuinely unsuitable: a history of serious bleeding, a bleeding disorder, or falls combined with other risks. The alternative is mechanical rather than pharmacological. The left atrial appendage, the pouch in which most of these clots form, can be closed off with a device delivered through a catheter, or in some cases closed surgically. This does not treat the rhythm and it is not free of risk, but for a patient who cannot take anticoagulants it addresses the place the clot actually comes from. The follow-up that keeps any of these plans on track is described on the prevention and follow-up page.

After the rhythm is restored: what is judged, and when

What happens after a rhythm is restored — by a shock or by an ablation — is a defined period rather than an open question. The days immediately afterwards are usually unremarkable: the puncture sites heal, the first day or two are spent being monitored, and most patients are back to ordinary activity quickly. What matters more is what is measured in the weeks that follow.

After an ablation the atrium is inflamed and irritable, and short runs of the rhythm, or of ectopic beats, are common in the first weeks. Clinicians therefore describe a settling period during which the result is not judged, and during which the anticoagulant is usually continued regardless of how the pulse feels. Judging the procedure before that period is over produces false reassurance and false disappointment in equal measure.

Follow-up after the settling period answers three questions: whether the rhythm has actually gone, what the rate is doing when the rhythm is normal, and whether the stroke-risk assessment has changed. Monitoring is repeated, medication is adjusted or reduced where that is safe, and the plan is written down for the patient's own cardiologist. The practical arrangements around all of this — what to bring, how long to plan for, and what the records look like — are covered on the practical questions page.

Frequently Asked Questions

Which is better — rate control or rhythm control?

Neither is better in general, and the comparison has been examined repeatedly without producing one winner. For a patient whose symptoms are mild and whose heart is not enlarged, rate control is often enough and involves less. For a patient whose episodes interfere with work or exercise, or whose heart is beginning to enlarge and weaken, going after the rhythm is usually worth discussing. The factors that move the decision towards rhythm control are mainly: younger age, a shorter history, a normal-sized atrium and symptoms that persist despite medication.

How likely is a second ablation to be needed?

Repeat procedures are a normal part of the pathway rather than an unusual event, because the tissue that was ablated can heal in a way that lets the electrical connection return, and because the atrium may develop new triggers over time. Whether a second procedure is worth doing is decided from monitoring rather than from a feeling: if the rhythm has returned and is causing symptoms, the options are re-examined on their merits — another procedure, a different drug, or a return to rate control. The first procedure is not therefore regarded as having failed.

Will I need a pacemaker?

For most patients with atrial fibrillation, no. A pacemaker question arises in three situations: when the rhythm is controlled and a persistently slow pulse or long pauses appear underneath it; when the conduction system has failed independently, sometimes showing itself as fainting; and when an AV node ablation has been chosen deliberately as a last resort for a rate that cannot be controlled any other way, in which case a pacemaker is part of the same plan rather than a complication of it.

Do I have to choose a treatment now?

No, provided the risk side of the problem is not being left unattended. When symptoms are mild, a plan of monitoring, periodic review and appropriate anticoagulation is a legitimate answer, and many patients stay on it for years without needing anything more. What makes waiting reasonable rather than negligent is that the rhythm is being watched and the stroke-risk conversation has actually happened. If either of those is missing, the delay is not a plan — it is simply a gap.

Patient Stories

Stories from our atrial fibrillation arrhythmia programme, pulled automatically from the patient story library by disease tag.

View all patient stories →

Ask for the comparison, not the procedure

Send us the tracings, the echocardiogram report, the medication list and a short account of how the episodes affect your days. A cardiology team will return a written opinion that sets the options side by side — rate control, rhythm control, ablation, anticoagulation — states which of them applies to you, and explains what each one would and would not change.

Want to see the whole process first? Your full medical journey, step by step →

Book an Appointment Request a Video Consultation

Follow Fosun Health

Apply for an Appointment

Do you have test results*